Is Dr. Lal PathLabs the Best Stock in Its Sector? A Look at the Numbers

Is Dr. Lal PathLabs the best stock in its sector? The stock trades on the NSE at Rs 1,950 as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60. Dr. Lal PathLabs Ltd, headquartered in New Delhi, is one of India's largest diagnostic chains, running laboratories, collection centres and a home sample collection network.

Dr. Lal PathLabs sits in the Healthcare sector, and its 20.13% ROE and 60.51x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Dr. Lal PathLabs

Dr. Lal PathLabs Ltd, headquartered in New Delhi, is one of India's largest diagnostic chains, running laboratories, collection centres and a home sample collection network. Pathology and diagnostic tests for patients, doctors and hospitals are its revenue source. The stock trades about 4 percent below its 52-week high and about 53 percent above its 52-week low. At a market capitalisation of Rs 33,058 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Dr. Lal PathLabs the Best Stock in Its Sector?

Dr. Lal PathLabs makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 20.13% ROE with a 60.51x P/E against the sector's 62.56x Industry P/E. Dr. Lal PathLabs' 60.51x P/E is slightly below the 62.56x Industry P/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table.

Metric	Dr. Lal PathLabs
CMP (NSE)	Rs 1,949.50
52-Week High / Low	Rs 2,038.60 / Rs 1,272.60
Market Cap	Rs 33,058 Cr
P/E (TTM) vs Industry P/E	60.51x vs 62.56x
P/B	13.18
ROE	20.13%
EPS (TTM)	Rs 32.55
Dividend Yield	1.04%
Debt to Equity	0.08

Compare Dr. Lal PathLabs Against Other Healthcare Sector Stocks

How Dr. Lal PathLabs Compares Against Its Healthcare Sector Peers

The table below sets Dr. Lal PathLabs against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Dr. Lal PathLabs	33,058	60.51	20.13%	0.08
Metropolis Healthcare	11,150	54.95	12.56%	0.15
Vijaya Diagnostic Centre	14,969	79.85	18.07%	0.44
Peer average (2 companies)	-	67.40	15.32%	0.29

Against this peer set, Dr. Lal PathLabs's 20.13% ROE is above the 15.32% peer average, and its P/E of 60.51x runs below the peer average of 67.40x. Dr. Lal PathLabs' 60.51x P/E is slightly below the 62.56x Industry P/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table.

What Makes Dr. Lal PathLabs Worth Watching in Healthcare

• Returns: A 20.13% ROE is higher than Metropolis Healthcare at 12.56% and Vijaya Diagnostic Centre at 18.07%.
• Valuation: A 60.51x P/E is below Vijaya Diagnostic Centre at 79.85x but above Metropolis Healthcare at 54.95x.
• Income: A dividend yield of 1.04% adds a modest income component.

Dr. Lal PathLabs Valuation: Is It Justified?

Dr. Lal PathLabs' 60.51x P/E is slightly below the 62.56x Industry P/E and below the 67.40x peer average, backed by a 20.13% ROE that is higher than both Metropolis Healthcare and Vijaya Diagnostic Centre and a debt to equity ratio of 0.08, the lowest in the peer table. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Dr. Lal PathLabs and other Healthcare sector stocks.

How to Track Dr. Lal PathLabs Before You Invest

Before deciding whether Dr. Lal PathLabs deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Dr. Lal PathLabs to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Dr. Lal PathLabs earns a place in the best stock in its sector conversation on the strength of a 20.13% ROE and a P/E of 60.51x against a 62.56x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Dr. Lal PathLabs the best stock in its sector?

Ans. Dr. Lal PathLabs has a 20.13% ROE and trades at 60.51x P/E against a 62.56x Industry P/E, and compares above the peer average ROE of 15.32% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Dr. Lal PathLabs?

Ans. Dr. Lal PathLabs was trading at Rs 1,949.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60.

What sector does Dr. Lal PathLabs belong to?

Ans. Dr. Lal PathLabs is classified under the Healthcare sector on Univest.

How does Dr. Lal PathLabs compare to its sector peers on P/E?

Ans. Dr. Lal PathLabs's P/E of 60.51x is below the 67.40x average of the 2 named peers compared in this article.

What is Dr. Lal PathLabs's return on equity?

Ans. Dr. Lal PathLabs reported a return on equity of 20.13%, which is above the 15.32% average of its named peers in this comparison.

Should I invest in Dr. Lal PathLabs based on its sector position?

Ans. Dr. Lal PathLabs's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Dr. Lal PathLabs the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs has a 20.13% ROE and trades at 60.51x P/E against a 62.56x Industry P/E, and compares above the peer average ROE of 15.32% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Dr. Lal PathLabs?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs was trading at Rs 1,949.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,272.60 to Rs 2,038.60."}}, {"@type": "Question", "name": "What sector does Dr. Lal PathLabs belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Dr. Lal PathLabs compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs's P/E of 60.51x is below the 67.40x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Dr. Lal PathLabs's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs reported a return on equity of 20.13%, which is above the 15.32% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Dr. Lal PathLabs based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Dr. Lal PathLabs's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}